Table 2.
Variable | No. of patients | Median DFS (mo) | p-valuea) | Median OS (mo) | p-valuea) |
---|---|---|---|---|---|
Age (yr) | 0.6466 | 0.4041 | |||
< 65 | 34 | 15.4 | 34.7 | ||
≥ 65 | 28 | 15.0 | 50.0 | ||
Gender | 0.1063 | 0.0432 | |||
Male | 31 | 10.5 | 23.8 | ||
Female | 31 | 22.5 | 61.3 | ||
Performance (ECOG) | 0.2269 | 0.3790 | |||
0-1 | 58 | 15.9 | 37.5 | ||
2 | 4 | 7.6 | 10.8 | ||
SA invasion | 0.0123 | 0.1084 | |||
Yes | 36 | 11.0 | 27.6 | ||
No | 26 | 49.2 | 68.6 | ||
SV invasion | 0.1723 | 0.5081 | |||
Yes | 43 | 15.4 | 37.5 | ||
No | 19 | 49.2 | 68.6 | ||
Tumor size (cm) | 0.2070 | 0.6161 | |||
< 3 | 27 | 17.3 | 37.5 | ||
≥ 3 | 35 | 12.4 | 45.8 | ||
RM involvement | 0.0002 | 0.0002 | |||
Yes | 11 | 8.2 | 16.3 | ||
No | 51 | 18.4 | 50.0 | ||
Lymph node metastasis | 0.1115 | 0.1994 | |||
Yes | 33 | 10.4 | 34.7 | ||
No | 29 | 27.6 | 50.0 | ||
Angiolymphatic invasion | 0.0503 | 0.0138 | |||
Yes | 18 | 8.2 | 13.8 | ||
No | 44 | 18.2 | 61.3 | ||
Venous invasion | 0.0008 | 0.0206 | |||
Yes | 16 | 10.4 | 18.5 | ||
No | 46 | 22.5 | 54.7 | ||
Perineural invasion | 0.0912 | 0.4778 | |||
Yes | 48 | 12.1 | 34.7 | ||
No | 12 | NR | 54.7 | ||
RT dose (Gy) | 0.3948 | 0.1978 | |||
< 50 | 13 | 10.4 | 22.0 | ||
≥ 50 | 49 | 17.3 | 54.7 | ||
Op-RT duration (day) | 0.7631 | 0.9182 | |||
< 45 | 32 | 18.4 | 37.5 | ||
≥ 45 | 30 | 11.0 | 50.0 | ||
Concurrent chemotherapy | 0.8668 | 0.8968 | |||
Gemcitabine | 16 | 10.1 | 17.9 | ||
Others | 46 | 16.5 | 37.5 |
DFS, disease-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; SA, splenic artery; SV, splenic vein; RM, resection margin; NR, not reached; RT, radiotherapy; Op, operation.
Log-rank test.